tetano
Editor, Senior Moderator
World J Hepatol
. 2023 Jan 27;15(1):68-78.
doi: 10.4254/wjh.v15.i1.68.
Clinical characteristics and outcomes of COVID-19 in patients with autoimmune hepatitis: A population-based matched cohort study
Arunkumar Krishnan[SUP] 1 2 [/SUP], Ruhee A Patel[SUP] 1 [/SUP], Yousaf Bashir Hadi[SUP] 1 [/SUP], Diptasree Mukherjee[SUP] 3 [/SUP], Sarah Shabih[SUP] 1 [/SUP], Shyam Thakkar[SUP] 1 [/SUP], Shailendra Singh[SUP] 1 [/SUP], Tinsay A Woreta[SUP] 4 [/SUP], Saleh A Alqahtani[SUP] 4 5 [/SUP]
Affiliations
Abstract
Background: Patients with autoimmune hepatitis (AIH) require life-long immunosuppressive agents that may increase the risk of poor coronavirus disease 2019 (COVID-19) outcomes. There is a paucity of large data at the population level to assess whether patients with AIH have an increased risk of severe diseases.
Aim: To evaluate the impact of pre-existing AIH on the clinical outcomes of patients with COVID-19.
Methods: We conducted a population-based, multicenter, propensity score-matched cohort study with consecutive adult patients (≥ 18 years) diagnosed with COVID-19 using the TriNeTx research network platform. The outcomes of patients with AIH (main group) were compared to a propensity score-matched cohort of patients: (1) Without chronic liver disease (CLD); and (2) Patients with CLD except AIH (non-AIH CLD) control groups. Each patient in the main group was matched to a patient in the control group using 1:1 propensity score matching to reduce confounding effects. The primary outcome was all-cause mortality, and secondary outcomes were hospitalization rate, need for critical care, severe disease, mechanical ventilation, and acute kidney injury (AKI). For each outcome, the risk ratio (RR) and confidence intervals (CI) were calculated to compare the association of AIH with the outcome.
Results: We identified 375 patients with AIH, 1647915 patients with non-CLD, and 15790 patients with non-AIH CLD with COVID-19 infection. Compared to non-CLD patients, the AIH cohort had an increased risk of all-cause mortality (RR = 2.22; 95%CI: 1.07-4.61), hospitalization rate (RR = 1.78; 95%CI: 1.17-2.69), and severe disease (RR = 1.98; 95%CI: 1.19-3.26). The AIH cohort had a lower risk of hospitalization rate (RR = 0.72; 95%CI: 0.56-0.92), critical care (RR = 0.50; 95%CI: 0.32-0.79), and AKI (RR = 0.56; 95%CI: 0.35-0.88) compared to the non-AIH CLD patients.
Conclusion: Patients with AIH are associated with increased hospitalization risk, severe disease, and all-cause mortality compared to patients without pre-existing CLD from the diagnosis of COVID-19. However, patients with AIH were not at risk for worse outcomes with COVID-19 than other causes of CLD.
Keywords: Autoimmune hepatitis; COVID-19; Liver disease; Mortality; Outcomes; SARS-CoV-2; Severe.
. 2023 Jan 27;15(1):68-78.
doi: 10.4254/wjh.v15.i1.68.
Clinical characteristics and outcomes of COVID-19 in patients with autoimmune hepatitis: A population-based matched cohort study
Arunkumar Krishnan[SUP] 1 2 [/SUP], Ruhee A Patel[SUP] 1 [/SUP], Yousaf Bashir Hadi[SUP] 1 [/SUP], Diptasree Mukherjee[SUP] 3 [/SUP], Sarah Shabih[SUP] 1 [/SUP], Shyam Thakkar[SUP] 1 [/SUP], Shailendra Singh[SUP] 1 [/SUP], Tinsay A Woreta[SUP] 4 [/SUP], Saleh A Alqahtani[SUP] 4 5 [/SUP]
Affiliations
- PMID: 36744163
- PMCID: PMC9896506
- DOI: 10.4254/wjh.v15.i1.68
Abstract
Background: Patients with autoimmune hepatitis (AIH) require life-long immunosuppressive agents that may increase the risk of poor coronavirus disease 2019 (COVID-19) outcomes. There is a paucity of large data at the population level to assess whether patients with AIH have an increased risk of severe diseases.
Aim: To evaluate the impact of pre-existing AIH on the clinical outcomes of patients with COVID-19.
Methods: We conducted a population-based, multicenter, propensity score-matched cohort study with consecutive adult patients (≥ 18 years) diagnosed with COVID-19 using the TriNeTx research network platform. The outcomes of patients with AIH (main group) were compared to a propensity score-matched cohort of patients: (1) Without chronic liver disease (CLD); and (2) Patients with CLD except AIH (non-AIH CLD) control groups. Each patient in the main group was matched to a patient in the control group using 1:1 propensity score matching to reduce confounding effects. The primary outcome was all-cause mortality, and secondary outcomes were hospitalization rate, need for critical care, severe disease, mechanical ventilation, and acute kidney injury (AKI). For each outcome, the risk ratio (RR) and confidence intervals (CI) were calculated to compare the association of AIH with the outcome.
Results: We identified 375 patients with AIH, 1647915 patients with non-CLD, and 15790 patients with non-AIH CLD with COVID-19 infection. Compared to non-CLD patients, the AIH cohort had an increased risk of all-cause mortality (RR = 2.22; 95%CI: 1.07-4.61), hospitalization rate (RR = 1.78; 95%CI: 1.17-2.69), and severe disease (RR = 1.98; 95%CI: 1.19-3.26). The AIH cohort had a lower risk of hospitalization rate (RR = 0.72; 95%CI: 0.56-0.92), critical care (RR = 0.50; 95%CI: 0.32-0.79), and AKI (RR = 0.56; 95%CI: 0.35-0.88) compared to the non-AIH CLD patients.
Conclusion: Patients with AIH are associated with increased hospitalization risk, severe disease, and all-cause mortality compared to patients without pre-existing CLD from the diagnosis of COVID-19. However, patients with AIH were not at risk for worse outcomes with COVID-19 than other causes of CLD.
Keywords: Autoimmune hepatitis; COVID-19; Liver disease; Mortality; Outcomes; SARS-CoV-2; Severe.